525 related articles for article (PubMed ID: 29267203)
21. Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer.
Sekhri K
J Postgrad Med; 2014; 60(3):303-8. PubMed ID: 25121374
[TBL] [Abstract][Full Text] [Related]
22. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Biology of Human Shelterin and Telomerase: Searching for the Weakest Point.
Veverka P; Janovič T; Hofr C
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261825
[TBL] [Abstract][Full Text] [Related]
24. Telomeres and telomerases as drug targets.
Rezler EM; Bearss DJ; Hurley LH
Curr Opin Pharmacol; 2002 Aug; 2(4):415-23. PubMed ID: 12127874
[TBL] [Abstract][Full Text] [Related]
25. Telomerase inhibitors in cancer therapy: current status and future directions.
Incles CM; Schultes CM; Neidle S
Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
[TBL] [Abstract][Full Text] [Related]
26. Telomere maintenance as a target for drug discovery.
Sekaran V; Soares J; Jarstfer MB
J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
[TBL] [Abstract][Full Text] [Related]
27. Telomerase inhibitors for the treatment of cancer: the current perspective.
Perry PJ; Arnold JR; Jenkins TC
Expert Opin Investig Drugs; 2001 Dec; 10(12):2141-56. PubMed ID: 11772310
[TBL] [Abstract][Full Text] [Related]
28. [Telomeres and telomerase, new targets for anticancer chemotherapy].
Riou JF; Morjani H; Trentesaux C
Ann Pharm Fr; 2006 Mar; 64(2):97-105. PubMed ID: 16568010
[TBL] [Abstract][Full Text] [Related]
29. Deactivation of Telomerase Enzyme and Telomere Destabilization by Natural Products: a Potential Target for Cancer Green Therapy.
Sasidharan S; Jothy SL; Kavitha N; Chen Y; Kanwar JR
Asian Pac J Cancer Prev; 2015; 16(18):8671. PubMed ID: 26745135
[No Abstract] [Full Text] [Related]
30. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T
Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747
[TBL] [Abstract][Full Text] [Related]
31. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
32. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
33. Targeting the telosome: therapeutic implications.
Folini M; Gandellini P; Zaffaroni N
Biochim Biophys Acta; 2009 Apr; 1792(4):309-16. PubMed ID: 19419699
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Targets in Telomerase and Telomere Biology of Cancers.
Prasad R; Pal D; Mohammad W
Indian J Clin Biochem; 2020 Apr; 35(2):135-146. PubMed ID: 32226245
[TBL] [Abstract][Full Text] [Related]
35. Prospects for anti-neoplastic therapies based on telomere biology.
Stewart SA; Hahn WC
Curr Cancer Drug Targets; 2002 Mar; 2(1):1-17. PubMed ID: 12188917
[TBL] [Abstract][Full Text] [Related]
36. Telomeres, telomerase and cancer: an endless search to target the ends.
Satyanarayana A; Manns MP; Rudolph KL
Cell Cycle; 2004 Sep; 3(9):1138-50. PubMed ID: 15467446
[TBL] [Abstract][Full Text] [Related]
37. Telomerase: a target for cancer therapeutics.
Shay JW; Wright WE
Cancer Cell; 2002 Oct; 2(4):257-65. PubMed ID: 12398889
[TBL] [Abstract][Full Text] [Related]
38. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
39. Berberine Inhibits Telomerase Activity and Induces Cell Cycle Arrest and Telomere Erosion in Colorectal Cancer Cell Line, HCT 116.
Samad MA; Saiman MZ; Abdul Majid N; Karsani SA; Yaacob JS
Molecules; 2021 Jan; 26(2):. PubMed ID: 33450878
[TBL] [Abstract][Full Text] [Related]
40. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Incles CM; Schultes CM; Kelland LR; Neidle S
Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
